Grace Therapeutics (GRCE) Change in Acquisitions & Divestments (2019 - 2024)

Grace Therapeutics has reported Change in Acquisitions & Divestments for 6 years, with the latest figure at $6.6 million in Q1 2024.

• Quarterly Change in Acquisitions & Divestments rose 31.38% year-over-year to $6.6 million in Q1 2024, while the trailing twelve-month figure through Mar 2026 was $6.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $15000.0, down 99.77% from the prior year.
• Change in Acquisitions & Divestments grew to $6.6 million in Q1 2024 per GRCE's latest filing, from $5.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $16.1 million in Q3 2021 and troughed at -$96000.0 in Q3 2022.
• A 5-year average of $6.7 million and a median of $5.8 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2021 and 2022: Change in Acquisitions & Divestments soared 76395.24% in 2021, then tumbled 100.6% in 2022.
• Over 5 years, Change in Acquisitions & Divestments stood at $21000.0 in 2020, then surged by 66000.0% to $13.9 million in 2021, then plunged by 100.69% to -$96000.0 in 2022, then soared by 5308.33% to $5.0 million in 2023, then surged by 31.38% to $6.6 million in 2024.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $6.6 million, $5.0 million, and -$96000.0 for Q1 2024, Q1 2023, and Q3 2022 respectively.